创新医疗(002173) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥161,392,113.23, representing a 5.80% increase compared to ¥152,545,362.35 in the same period last year[8] - The net profit attributable to shareholders was -¥24,053,643.08, an improvement of 34.07% from -¥36,481,490.93 year-over-year[8] - The basic and diluted earnings per share were both -¥0.05, showing a 37.50% improvement from -¥0.08 in the same quarter last year[8] - The company reported a net profit of -24,053,600 RMB for Q1 2021, and expects a net profit between -45,000,000 RMB and -55,000,000 RMB for the first half of 2021[35] - The company reported a net loss of CNY 1,103,004,742.53 in retained earnings, worsening from a loss of CNY 1,078,951,099.45[49] - The company reported a significant increase in non-current liabilities, which rose by 44,353,515.15 CNY to 229,254,167.28 CNY[71] Cash Flow - The net cash flow from operating activities was -¥9,888,396.53, which is a decline of 31.01% compared to -¥7,547,618.02 in the previous year[8] - The company reported cash and cash equivalents at the end of Q1 2021 amounting to 276,245,532.99, down from 737,692,806.59 at the end of the previous year[65] - Cash received from investment recoveries rose by 200.00% to RMB 150,000,000.00, mainly from the redemption of financial products[16] - The net cash flow from investment activities was -35,194,627.87 CNY, with total cash outflow from investment activities amounting to 146,649,505.89 CNY[68] - The net cash flow from financing activities was -29,755,500.00 CNY, with total cash outflow from financing activities also at 29,755,500.00 CNY[68] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,679,506,200.77, a slight increase of 0.07% from ¥2,677,542,017.40 at the end of the previous year[8] - The company's current assets decreased to CNY 1,048,422,132.04 from CNY 1,119,950,091.87, representing a decline of approximately 6.4%[46] - The total liabilities of the company rose to CNY 588,846,834.73 from CNY 533,105,022.97, marking an increase of about 10.5%[48] - The total equity attributable to shareholders decreased to CNY 2,089,628,613.84 from CNY 2,143,437,756.92, a decline of approximately 2.5%[49] - The company's total current liabilities increased to 368,574,594.44 CNY, indicating a rise in short-term financial obligations[71] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,779[12] - The largest shareholder, Chen Xiaying, holds 17.06% of the shares, with a total of 77,616,997 shares[12] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[13] - The company repurchased shares amounting to RMB 29,755,500.00 during the reporting period[16] - The company repurchased a total of 7,758,700 shares, accounting for 1.71% of the total share capital, with a total transaction amount of RMB 48,396,390.66[23] Legal Proceedings - The company is involved in ongoing legal proceedings related to various disputes, which may impact future financial performance[18][19][21] - The company has initiated legal proceedings against the Industrial and Commercial Bank of China regarding the forced deduction of RMB 24.969 million from its fundraising account[22] - The company is appealing a court ruling related to a dispute with 富浙资本, which has not yet been resolved[23] - The company has received a civil lawsuit from 富浙资本 regarding a company resolution dispute, which is still pending judgment[23] Investments and Projects - Long-term equity investments of RMB 20,000,000.00 were made in a "brain-computer interface" project company[16] - The company established a joint venture for the "brain-computer interface" project with a registered capital of RMB 50 million, contributing RMB 20 million, which represents 40% of the total[24] - The company has invested RMB 55,000,000 in bank wealth management products using temporarily idle raised funds[37] - The company has temporarily suspended the construction of the internal medicine outpatient comprehensive building at Jianhua Hospital due to insufficient business volume[34] - The company plans to continue the construction of the "Kanghua Hospital Phase II Outpatient Building" project with the remaining funds from the completed Phase II project[34]